Financial Performance - The company's operating revenue for 2024 was ¥708,834,125.46, representing a 1.57% increase compared to ¥697,893,051.87 in 2023[21]. - Net profit attributable to shareholders for 2024 was ¥64,571,985.96, an increase of 8.31% from ¥59,615,904.53 in 2023[21]. - The net profit after deducting non-recurring gains and losses was ¥61,440,085.63, up 9.02% from ¥56,354,683.13 in 2023[21]. - Cash flow from operating activities significantly increased by 156.81% to ¥236,060,400.80 from ¥91,921,049.09 in 2023[21]. - The total assets at the end of 2024 reached ¥1,619,459,478.19, an 8.58% increase from ¥1,491,487,005.16 at the end of 2023[21]. - The company reported a basic earnings per share of ¥0.62 for 2024, a 10.71% increase from ¥0.56 in 2023[21]. - The total net profit for the company after deducting non-recurring gains and losses was ¥3,131,900.33 in 2024, slightly down from ¥3,261,221.40 in 2023[27]. - The company's total revenue for the reporting period was 657,666,703.25 CNY, with a year-on-year increase of 0.98%[60]. - The gross profit margin for the pharmaceutical intermediates segment was 16.08%, reflecting a slight increase of 0.10% compared to the previous year[60]. Dividend Distribution - The company plans to distribute a cash dividend of 2.00 RMB per 10 shares (including tax) to all shareholders, with no bonus shares issued[4]. - The company plans to distribute cash dividends of RMB 2.00 per 10 shares, totaling RMB 20,634,527.60 (including tax), with a distribution ratio of 100% of the profit distribution total[153]. - The total number of shares for the cash dividend distribution is based on 103,172,638 shares, excluding 2,847,362 shares held in the repurchase account[154]. - The company has repurchased 2,847,362 shares at a total cost of RMB 50,002,854.65 (excluding transaction fees), with the total cash dividend and share repurchase amounting to RMB 70,637,382.25, representing 109.39% of the net profit attributable to shareholders for the fiscal year 2024[154]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements in the annual report[4]. - The company's management discusses potential risks and countermeasures in the section on future development outlook[4]. - The company is committed to optimizing internal controls and risk management, enhancing overall business management levels through independent audits and supervision[56]. - The company recognizes risks from macroeconomic fluctuations and will adapt its strategies to mitigate potential impacts on business operations[109]. Technological Innovation - The company has established three major technology platforms for synthetic technology[15]. - The company is focusing on technological innovation and supply chain restructuring to capitalize on structural opportunities in the quinolone intermediate industry[32]. - The company is actively pursuing new product development through its three major technology platforms, including carbonylation and continuous flow reaction technologies[48]. - The company is committed to increasing R&D investment and technical reserves to enhance its core technology development and accumulation, aiming to maintain a technological leadership advantage[187]. Environmental Responsibility - The company emphasizes clean production processes and has implemented measures to minimize environmental impact[167]. - The company has established a comprehensive environmental risk emergency mechanism, with a plan effective for three years[168]. - The company conducts regular environmental self-monitoring and engages qualified testing units for periodic assessments[169]. - The company reported a total nitrogen discharge of 3.613 tons, well below the regulatory limit of 70 mg/L[166]. - The company reported a sulfur dioxide emission of 0.54 tons, significantly lower than the allowable limit of 200 mg/m³[166]. - The company's environmental protection expenditure amounted to RMB 22.4265 million, including costs for waste disposal and maintenance of environmental facilities[170]. Governance and Compliance - The company has established a comprehensive governance structure with a board of directors, supervisory board, and management team, ensuring independent operations[120]. - The board of directors consists of 7 members, including 3 independent directors, ensuring diverse expertise and independent decision-making[116]. - The company strictly adheres to information disclosure obligations, ensuring that all investors have equal access to information, thereby protecting the rights of minority investors[118]. - The company has implemented a comprehensive internal control system to ensure accurate financial reporting[161]. - The audit committee has conducted thorough internal audits and found no issues during the reporting period[145]. Market Expansion and Sales - The company expanded its international market, with foreign sales reaching 188.58 million CNY, a 17.88% increase from the previous year[58]. - The pharmaceutical intermediates segment contributed 657.67 million CNY, accounting for 92.78% of total revenue, with a year-on-year growth of 0.98%[58]. - The company increased its direct sales model revenue to 591.74 million CNY, representing 83.48% of total revenue, with a significant growth of 20.87%[58]. - The company is positioned to support high-quality and green development in the pesticide industry, aligning with national policies[34]. Employee Management - The total number of employees at the end of the reporting period is 489, with 473 in the parent company and 16 in major subsidiaries[146]. - The company has established a comprehensive human resources management system to protect employee rights and promote talent development[174]. - The company implements a differentiated salary system based on job responsibilities, performance, and individual capabilities[148]. - The company is committed to continuously improving the performance evaluation mechanism to enhance employee skills and work efficiency[148]. Financial Management - The company has a total of ¥7,392,000.00 in cash as guarantee deposits, indicating a commitment to secure financial obligations[86]. - The company has not engaged in any securities or derivative investments during the reporting period[88][89]. - The company has committed to invest in projects with a total fundraising amount of 14.3 million yuan, with a completion rate of 50.2% as of the report date[93]. - The company has not reported any significant accounting policy changes or errors during the reporting period[194]. Shareholder Relations - The company actively engages with shareholders, providing opportunities for participation in decision-making processes[116]. - The company will ensure compliance with relevant laws and regulations regarding shareholder rights and related transactions[184]. - The company will publicly explain any failure to fulfill commitments in the prospectus on designated websites if such failures occur[189]. - The company has 20 shareholders, including 18 natural persons and 2 partnership enterprises, and has disclosed shareholder information accurately and completely in the prospectus[189].
本立科技(301065) - 2024 Q4 - 年度财报